These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1147 related items for PubMed ID: 17590247

  • 1. Plasminogen activator system in oral squamous cell carcinoma.
    Baker EA, Leaper DJ, Hayter JP, Dickenson AJ.
    Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
    [Abstract] [Full Text] [Related]

  • 2. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 3. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
    Pedersen H, Brünner N, Francis D, Osterlind K, Rønne E, Hansen HH, Danø K, Grøndahl-Hansen J.
    Cancer Res; 1994 Sep 01; 54(17):4671-5. PubMed ID: 8062262
    [Abstract] [Full Text] [Related]

  • 4. Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value.
    Hundsdorfer B, Zeilhofer HF, Bock KP, Dettmar P, Schmitt M, Kolk A, Pautke C, Horch HH.
    J Craniomaxillofac Surg; 2005 Jun 01; 33(3):191-6. PubMed ID: 15878520
    [Abstract] [Full Text] [Related]

  • 5. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N, Maguire TM, Riisbro R, Geurts-Moespot A, O'Donovan N, Schmitt M, McGreal G, McDermott E, O'Higgins N, Brünner N, Sweep CG, Duffy MJ.
    Oncol Rep; 2005 Jul 01; 14(1):235-9. PubMed ID: 15944795
    [Abstract] [Full Text] [Related]

  • 6. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ, Mooy CM, Van Balken MR, Luyten GP, Quax PH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GN.
    J Pathol; 1995 Jan 01; 175(1):59-67. PubMed ID: 7891228
    [Abstract] [Full Text] [Related]

  • 7. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S, Vrhovec I, Svetic B, Cufer T.
    Clin Breast Cancer; 2002 Jun 01; 3(2):138-46. PubMed ID: 12123538
    [Abstract] [Full Text] [Related]

  • 8. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 9. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 10. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K.
    Cancer; 1996 Aug 01; 78(3):487-92. PubMed ID: 8697395
    [Abstract] [Full Text] [Related]

  • 11. Cathepsin B, plasminogenactivator-inhibitor (PAI-1) and plasminogenactivator-receptor (uPAR) are prognostic factors for patients with non-small cell lung cancer.
    Werle B, Kotzsch M, Lah TT, Kos J, Gabrijelcic-Geiger D, Spiess E, Schirren J, Ebert W, Fiehn W, Luther T, Magdolen V, Schmitt M, Harbeck N.
    Anticancer Res; 2004 Aug 01; 24(6):4147-61. PubMed ID: 15736466
    [Abstract] [Full Text] [Related]

  • 12. Detection of plasminogen activators in oral cancer by laser capture microdissection combined with zymography.
    Curino A, Patel V, Nielsen BS, Iskander AJ, Ensley JF, Yoo GH, Holsinger FC, Myers JN, El-Nagaar A, Kellman RM, Shillitoe EJ, Molinolo AA, Gutkind JS, Bugge TH.
    Oral Oncol; 2004 Nov 01; 40(10):1026-32. PubMed ID: 15509494
    [Abstract] [Full Text] [Related]

  • 13. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
    Wang J, Guo F, Wei H, Dong J, Wu J.
    Br J Oral Maxillofac Surg; 2006 Dec 01; 44(6):515-9. PubMed ID: 16356605
    [Abstract] [Full Text] [Related]

  • 14. Spitz naevi may express components of the plasminogen activation system.
    Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ.
    J Pathol; 2002 Sep 01; 198(1):92-9. PubMed ID: 12210068
    [Abstract] [Full Text] [Related]

  • 15. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG.
    Cancer Res; 2000 Feb 01; 60(3):636-43. PubMed ID: 10676647
    [Abstract] [Full Text] [Related]

  • 16. Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma.
    Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U, Kocijancic B.
    Oncol Rep; 2003 Feb 01; 10(3):635-9. PubMed ID: 12684636
    [Abstract] [Full Text] [Related]

  • 17. Changes in plasminogen activator inhibitor-1 levels in non-small cell lung cancer.
    Pavey SJ, Marsh NA, Ray MJ, Butler D, Dare AJ, Hawson GA.
    Boll Soc Ital Biol Sper; 1996 Feb 01; 72(11-12):331-40. PubMed ID: 9178585
    [Abstract] [Full Text] [Related]

  • 18. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
    Yoshizawa K, Nozaki S, Kitahara H, Kato K, Noguchi N, Kawashiri S, Yamamoto E.
    Oncol Rep; 2011 Dec 01; 26(6):1555-60. PubMed ID: 21833477
    [Abstract] [Full Text] [Related]

  • 19. Urokinase plasminogen activator and plasminogen activator inhibitor type-1 in nonsmall-cell lung cancer: relation to prognosis and angiogenesis.
    Offersen BV, Pfeiffer P, Andreasen P, Overgaard J.
    Lung Cancer; 2007 Apr 01; 56(1):43-50. PubMed ID: 17207889
    [Abstract] [Full Text] [Related]

  • 20. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
    Kumamoto H, Ooya K.
    J Oral Pathol Med; 2007 Sep 01; 36(8):488-94. PubMed ID: 17686008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.